The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index.
Declining Differences in Response Rates with Antidepressants versus Placebo: A Modest Proposal for Another Contributing Cause
Abstract
This column discusses declining differences in response rates between sequentially introduced selective serotonin reuptake inhibitors (SSRI) and placebo. Although discussions of this phenomenon in the literature have largely focused on increasing placebo response rates, the author proposes that another factor may be responsible. That factor is an order effect, meaning that response rates have been declining as a function of the number of SSRIs on the market when the next SSRI is in development. The rationale is that the pool of potential clinical trial participants likely to respond to a drug with this mechanism of action (MOA) becomes progressively smaller with the introduction of each new agent with the same MOA, because many patients will already have been treat- ed and responded to an earlier member of the class. This phenomenon is not limited to the SSRIs but generalizes to any class of treatments that shares the same MOA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, nonresponse rates have been estimated to be as high as 45–50% (Preskorn, 2013; Spijker et al., 2002).”
From A mindful yoga intervention for young women with major depressive disorder: Design and baseline sample characteristics of a randomized controlled trial (2020) · cites this paper as Preskorn, 2013
In the citing paper
“rates of response to the intervention (Cuijpers et al., 2013; Preskorn, 2013; Spijker et al., 2002)”
From A mindful yoga intervention for young women with major depressive disorder: Design and baseline sample characteristics of a randomized controlled trial (2020) · cites this paper as Preskorn, 2013
In the citing paper
“modest rates of treatment response (Preskorn, 2013; Spijker et al., 2012)”
From A mindful yoga intervention for young women with major depressive disorder: Design and baseline sample characteristics of a randomized controlled trial (2020) · cites this paper as Preskorn, 2013
Citations
Cites
An effect size primer: A guide for clinicians and researchers.
Ferguson, C. J. (2009) · Professional Psychology: Research and Practice · doi:10.1037/a0015808 · Cited by 3,467
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Measures of Clinical Significance
KRAEMER, H. C., MORGAN, G. A., LEECH, N. L., GLINER, J. A., VASKE, J. J., & HARMON, R. J. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00022 · Cited by 367
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302
Self-citationReporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials
Nuovo, J. (2002) · JAMA · doi:10.1001/jama.287.21.2813 · Cited by 241
CNS Drug Development: Part I: The Early Period of CNS Drugs
Preskorn, S. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000388628.44405.c0 · Cited by 35
Self-citationResults of the STAR*D Study: Implications for Clinicians and Drug Developers
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344918.51404.1e · Cited by 28
Self-citationThe Use of Biomarkers in Psychiatric Research
Preskorn, S. (2012) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000410986.61593.46 · Cited by 22
Self-citation
Flagged first, then by citations
2 of the 18 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kalia, 2011, Vilazodone for major depressive disorder., Curr Psychiatry, 10, 84
Cited by
Sorted by citations
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Daly, E., Turkoz, I., Salvadore, G., Fedgchin, M. M., Ionescu, D. F., Starr, H. L., Borentain, S., Trivedi, M. H., Thase, M. E., & Singh, J. B. (2021) · Depression and Anxiety · doi:10.1002/da.23193 · Cited by 47
Therapeutic Drug Monitoring (TDM) in Psychiatry (Part I)
Preskorn, S. (2014) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000445247.54048.68 · Cited by 35
Self-citationJones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 33
Cohen, S. E., Zantvoord, J. B., Storosum, B. W. C., Mattila, T., Daams, J. G., Wezenberg, B. N., de Boer, A., & Denys, D. A. J. P. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2023-300951 · Cited by 20
Metadata
- Authors
- PRESKORN, S. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- PRESKORN, SHELDON H.
- Venue
- Journal of Psychiatric Practice
- Published
- 2013-05
- Volume
- 19
- Issue
- 3
- Pages
- 227-233
- ISSN
- 1527-4160 (ISSN-L)
- 1538-1145
- OpenAlex
- W2048542310
- Cited by
- 12
- References
- 18
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 1 · 2013: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychiatric Practice (publishedVersion)
- PubMed (publishedVersion)
- Holmes Museum Of Anthropology (Wichita State University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- antidepressants, selective serotonin reuptake inhibitors, placebo response, treatment response rate, order effects, mechanism of action, clinical trial participants, drug development
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Drug Utilization, Humans, United States, United States Food and Drug Administration, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome, Drug Approval, Selective Serotonin Reuptake Inhibitors, Drug Substitution, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
